Citation Impact
Citing Papers
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
2009 StandoutScience
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
2015
Bioluminescent imaging of Cdk2 inhibition in vivo
2004 StandoutNobel
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
2005 StandoutNobel
Estrogen receptors and human disease
2006 Standout
The FGF family: biology, pathophysiology and therapy
2009 Standout
Role of estrogens in development of prostate cancer
2004
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
1998
Epigenetics in human disease and prospects for epigenetic therapy
2004 StandoutNature
Cancer Metastasis: Building a Framework
2006 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines
2005
Dissemination and growth of cancer cells in metastatic sites
2002 Standout
The antiandrogen withdrawal syndrome
1997
Tumor Angiogenesis, Macrophages, and Cytokines
2000
Molecular determinants of resistance to antiandrogen therapy
2003 Standout
Racial and Ethnic Disparities in the Receipt of Cancer Treatment
2002
The Epigenomics of Cancer
2007 Standout
Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
1999
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Phase II Trial of Toremifene in Androgen-Independent Prostate Cancer
2001
The microenvironment of the tumour–host interface
2001 StandoutNature
Structural features underlying selective inhibition of protein kinase CK2 by ATP site‐directed tetrabromo‐2‐benzotriazole
2001
Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)
2001
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals
2003 Standout
Blocking Oncogenic Ras Signaling for Cancer Therapy
2001
DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action
2000
Plant Polyphenols: Chemical Properties, Biological Activities, and Synthesis
2011 Standout
Reactivating the expression of methylation silenced genes in human cancer
2002
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
Competition and Compensation
2002 Standout
The CDK inhibitors in cancer research and therapy
2011
Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors
2004
Thalidomide
2004
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
2007
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
Glutamine addiction: a new therapeutic target in cancer
2010
Current strategies in the management of hormone refractory prostate cancer
2003
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2003 Standout
The molecular basis and potential role of survivin in cancer diagnosis and therapy
2001
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer
2002
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA
2015 StandoutNobel
The fundamental role of epigenetic events in cancer
2002 Standout
Tumor Angiogenesis
2008 Standout
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
Head and Neck Cancer
2001 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors
2000
Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas
2007
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
1999
Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone
2000
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Copper-Mediated Coupling Reactions and Their Applications in Natural Products and Designed Biomolecules Synthesis
2008 Standout
The kinase Grk2 regulates Nedd4/Nedd4-2-dependent control of epithelial Na + channels
2004 StandoutNobel
Synthesis, Structure−Activity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors
2003
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Prostate Specific Antigen Decreases After Withdrawal of Antiandrogen Therapy with Bicalutamide or Flutamide in Patients Receiving Combined Androgen Blockade
1997
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
2005 Standout
The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
2011
The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry
2007 Standout
STEROID HORMONE WITHDRAWAL SYNDROMES
1997
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
2002
Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients
2004
Aryl−Aryl Bond Formation by Transition-Metal-Catalyzed Direct Arylation
2007 Standout
Paullones, a Series of Cyclin-Dependent Kinase Inhibitors: Synthesis, Evaluation of CDK1/Cyclin B Inhibition, and in Vitro Antitumor Activity
1999 Standout
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
1999
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells
1999
Frequent loss of estrogen receptor-beta expression in prostate cancer.
2001
First Total Synthesis of Naturally Occurring (−)‐Nitidon and Its Enantiomer
2004
Flavopiridol, A Novel Cyclin-Dependent Kinase Inhibitor, in Metastatic Renal Cancer: A University of Chicago Phase II Consortium Study
2000
Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: Newde NovoDesign Strategy and Library Design
2001
Activation of the p53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2′-deoxycytidine
2001
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
The Halogen Bond
2016 Standout
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Expression of BCL-2 Oncoprotein and P53 Protein Accumulation in Bone Marrow Metastases of Androgen Independent Prostate Cancer
1997
Studies in Polyphenol Chemistry and Bioactivity. 4.1 Synthesis of Trimeric, Tetrameric, Pentameric, and Higher Oligomeric Epicatechin-Derived Procyanidins Having All-4β,8-Interflavan Connectivity and Their Inhibition of Cancer Cell Growth through Cell Cycle Arrest1
2002
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
2007 StandoutNobel
Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications
2001
Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis
2012
Idiopathic Pulmonary Fibrosis
2018 Standout
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
2006
The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic Stroke
2008
Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins
2001
Works of A Tompkins being referenced
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
1997
Pharmacokinetics of thalidomide in an elderly prostate cancer population
1999
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
1998
Phase I study of phenylacetate administered twice daily to patients with cancer
1995
A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer
1998
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
1999
Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer
1994
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
2001
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
1994
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
1996
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
2001
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
1997